AR019694A1 - METHOD FOR THE TREATMENT OR REDUCTION OF FEMALE SEXUAL DYSFUNCTION. - Google Patents

METHOD FOR THE TREATMENT OR REDUCTION OF FEMALE SEXUAL DYSFUNCTION.

Info

Publication number
AR019694A1
AR019694A1 ARP990102966A ARP990102966A AR019694A1 AR 019694 A1 AR019694 A1 AR 019694A1 AR P990102966 A ARP990102966 A AR P990102966A AR P990102966 A ARP990102966 A AR P990102966A AR 019694 A1 AR019694 A1 AR 019694A1
Authority
AR
Argentina
Prior art keywords
reduction
vaginal
apomorphine
female
treatment
Prior art date
Application number
ARP990102966A
Other languages
Spanish (es)
Original Assignee
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston filed Critical Univ Kingston
Publication of AR019694A1 publication Critical patent/AR019694A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método de tratamiento de la disfuncion sexual en una hembra, incluyendo los síntomas vasculogénicos del retraso en la congestion vaginal, la reduccionde la lubricacion vaginal, el dolor o las molestias en el coito (dispareunia), la reduccion de lasensacion vaginal, la reduccion del orgasmo vaginal, lareduccion de la sensacion clitorica o la reduccion del orgasmo clitorico, o para combatir el dolor vaginal estimulando la liberacion por los nervios pélvicosperiféricos de oxido nítrico (NO). Elmétodo consiste en administrar a una hembra que necesite dicho tratamiento una cantidad terapéuticamente efectiva de uncompuesto que actua sobre una ruta del cerebro medio para aumentar el flujo sanguíneo al lecho arterial ilio-hipogástrico-pudendoy estimular la liberacion deoxido nítrico (NO) por las células nerviosas NANC periféricas. El compuesto preferido para el método es la apomorfina o una de sus sales, ésteres o profármacosfarmacéuticamente aceptables. Alternativamente, la apormorfinaes coadministrada con una cantidad potenciadora de la apomorfina de un androgeno,preferiblemente testosterona ya sea antes de, o al mismo tiempo que, la administracion de la apomorfina.A method of treating sexual dysfunction in a female, including vasculogenic symptoms of delayed vaginal congestion, reduction of vaginal lubrication, pain or discomfort in intercourse (dyspareunia), reduction of vaginal sensation, reduction of vaginal orgasm, reduction of clitoral sensation or reduction of clitoral orgasm, or to combat vaginal pain by stimulating the release by pelvic nerves of peripheral nitric oxide (NO). The method consists of administering to a female in need of such treatment a therapeutically effective amount of a compound that acts on a path of the middle brain to increase blood flow to the ilio-hypogastric arterial bed - and can stimulate the release of nitric oxide (NO) by nerve cells. Peripheral NANC. The preferred compound for the method is apomorphine or one of its pharmaceutically acceptable salts, esters or prodrugs. Alternatively, apormorphine is co-administered with an apomorphine-enhancing amount of an androgen, preferably testosterone either before, or at the same time as, the administration of apomorphine.

ARP990102966A 1998-06-22 1999-06-22 METHOD FOR THE TREATMENT OR REDUCTION OF FEMALE SEXUAL DYSFUNCTION. AR019694A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10298798A 1998-06-22 1998-06-22

Publications (1)

Publication Number Publication Date
AR019694A1 true AR019694A1 (en) 2002-03-13

Family

ID=22292763

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102966A AR019694A1 (en) 1998-06-22 1999-06-22 METHOD FOR THE TREATMENT OR REDUCTION OF FEMALE SEXUAL DYSFUNCTION.

Country Status (7)

Country Link
EP (1) EP1089736A2 (en)
JP (1) JP2002518435A (en)
AR (1) AR019694A1 (en)
AU (1) AU4254799A (en)
CA (1) CA2334550A1 (en)
MX (1) MXPA01000275A (en)
WO (1) WO1999066909A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0005797A (en) * 2000-03-20 2001-10-16 Abbott Lab Methods for the treatment of sexual dysfunction with apomorphine at specified plasma concentration levels
IL151614A0 (en) * 2000-04-07 2003-04-10 Tap Holdings Inc Apomorphine derivatives and methods for their use
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
FI20002756A0 (en) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj New treatment procedure
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
GB0204919D0 (en) * 2002-03-01 2002-04-17 Cst Medical Ltd Treatment of female sexual dysfunction
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212952A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
SU1421258A3 (en) * 1984-08-02 1988-08-30 Эли Лилли Энд Компани (Фирма) Method of producing transoctahydrooxasol (4,5q) quinoline or its pharmaceutically acceptable salts
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
EP0641202A1 (en) * 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
WO1999066909A2 (en) 1999-12-29
MXPA01000275A (en) 2002-04-24
JP2002518435A (en) 2002-06-25
CA2334550A1 (en) 1999-12-29
EP1089736A2 (en) 2001-04-11
WO1999066909A3 (en) 2000-06-29
AU4254799A (en) 2000-01-10

Similar Documents

Publication Publication Date Title
Bartlik et al. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors
PE20010925A1 (en) NEUROPEPTIDE INHIBITING COMPOUNDS AND USEFUL FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
CR5959A (en) TREATMENT FOR FEMALE SEXUAL DYSFUNCTION
NI201100147A (en) METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS.
DK1173178T3 (en) Composition comprising apomorphine and sildenafil and its use in the treatment of erectile dysfunction
ES2165990T3 (en) THIP FOR THE TREATMENT OF SLEEP DISORDERS.
Yajnik et al. Phenytoin as a coanalgesic in cancer pain
EE200200107A (en) Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction
AR019694A1 (en) METHOD FOR THE TREATMENT OR REDUCTION OF FEMALE SEXUAL DYSFUNCTION.
EA201992759A1 (en) ASSOCIATION INCLUDING OXYGEN AND HYALURONIC ACID, FOR LOCAL VAGINAL USE
CO5251425A1 (en) METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS
SI2694065T1 (en) Composition for treating hypoactive sexual desire disorder
ES2042818T3 (en) THERAPEUTIC AGENT FOR THROMBOCITOPENIA.
RU2475241C1 (en) Method of treating acute orchiepididymitis and their complications
Sato Silodosin improved spontaneous ejaculation induced by mental strain.
RU2020108631A (en) NEW SUPPLEMENTARY THERAPY FOR USE IN THE METHOD OF TREATMENT OF PROSTATE CANCER
Schwartz Effectiveness of penicillin in the treatment of Vincent's angina
RU2695594C1 (en) Method of treating complicated ejaculation in tuberculosis patients
AR026506A1 (en) A MEDICATION FOR THE PREVENTION AND TREATMENT OF SEXUAL DYSFUNCTION
KR100324447B1 (en) Pharmaceutical composition for treating male sexual dysfunction containing atipamezole
RU2048808C1 (en) Agent stimulating potency
SU1044286A1 (en) Method of treating trigeminal nerve neuralgia
RO134193A2 (en) Pharmaceutical composition for treatment of male gonadal dysfunction and sterility
RU2180223C1 (en) Agent for treatment of men with erection disorder
BR112015009936A2 (en) method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction but wishing to have sexual activity; use of a formulation dose; bremelanotide for use in a method for treating female sexual dysfunction; and preloaded dose unit

Legal Events

Date Code Title Description
FB Suspension of granting procedure